SeaStar Medical (NASDAQ:ICU) Stock Price Up 1.3% – Time to Buy?

Shares of SeaStar Medical Holding Corporation (NASDAQ:ICU) rose 1.3% on Monday . The company traded as high as $3.08 and last traded at $3.07. 11,203 shares traded hands during mid-day trading, a decline of 76% from the average daily volume of 47,014 shares. The stock had previously closed at $3.03.

Analysts Set New Price Targets

ICU has been the topic of several recent research reports. Wall Street Zen lowered shares of SeaStar Medical from a “hold” rating to a “sell” rating in a research report on Sunday, August 23rd. Weiss Ratings restated a “sell (e+)” rating on shares of SeaStar Medical in a report on Friday, July 17th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $8.00.

SeaStar Medical Stock Performance

The business has a fifty day simple moving average of $3.53 and a 200 day simple moving average of $3.52. The stock has a market cap of $13.54 million, a price-to-earnings ratio of -0.79 and a beta of -1.05.

SeaStar Medical (NASDAQ:ICU) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.91) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.06. SeaStar Medical had a negative return on equity of 162.75% and a negative net margin of 795.51%.The company had revenue of $0.61 million during the quarter, compared to analysts’ expectations of $0.49 million. On average, equities research analysts anticipate that SeaStar Medical Holding Corporation will post -3.66 EPS for the current fiscal year.

SeaStar Medical Company Profile

SeaStar Medical, Inc (NASDAQ: ICU) is a medical device company focused on the development and commercialization of cerebral embolic protection systems for patients undergoing transcatheter aortic valve replacement (TAVR) procedures. The company’s mission is to reduce the risk of stroke and other neurologic events associated with structural heart interventions by capturing or deflecting embolic debris that can travel to the brain during catheter-based therapies.

The company’s flagship product, TriGUARD® 3, is a next-generation embolic deflection device designed to provide coverage of all three cerebral vessels during TAVR.